Galectin Therapeutics Inc.
GALTAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Dec 17, 2025 | H.C. Wainwright | Matthew Keller | $11.00(+77%) | $6.20 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Jun 23, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 17, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Apr 2, 2025 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Dec 27, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 17, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 3, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 17, 2022 |
| HC Wainwright & Co. | maintain | Buy | Apr 16, 2021 |
| HC Wainwright & Co. | maintain | Buy | Aug 13, 2020 |
| B. Riley FBR | maintain | Buy | Apr 3, 2020 |
| B. Riley Securities | maintain | Buy | Apr 3, 2020 |
| HC Wainwright & Co. | maintain | Buy | Mar 17, 2020 |
| B. Riley FBR | maintain | Buy | Feb 13, 2019 |
| Roth Capital | maintain | Buy | Oct 19, 2017 |
| Seaport Global | maintain | Buy | Oct 6, 2017 |
| H.C. Wainwright | upgrade | Neutral →Buy | Mar 30, 2017 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Mar 30, 2017 |
| FBR Capital | downgrade | Outperform →Market Perform | Oct 3, 2016 |
| H.C. Wainwright | downgrade | Buy →Neutral | Sep 29, 2016 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.05| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.14 | $-0.09 | — | — |
| May 15, 2026 | $-0.08 | $-0.06 | — | — |
| Mar 31, 2026 | $-0.08 | $-0.10 | — | $36.3M |
| Nov 14, 2025 | $-0.13 | $-0.11 | — | — |
| Aug 14, 2025 | $-0.12 | $-0.16 | — | — |
| May 15, 2025 | $-0.15 | $-0.20 | — | — |
| Mar 31, 2025 | $-0.19 | $-0.16 | $36.0K | — |
| Nov 14, 2024 | $-0.18 | $-0.20 | — | — |
News
Galectin Therapeutics will present new clinical findings at American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Denver. These results will be covered in one oral presentation and two posters including a Poster of Distinction.
NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver Meeting 2026. The Company will deliver three presentations, including an oral presentation, a Poster of Distinction presentation, and one poster presentation, highlighting new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b tr…
NORCROSS, Ga., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that company management will present and attend the H.C.
SQZ Biotechnologies (NYSE: SQZ - Get Free Report) and Galectin Therapeutics (NASDAQ: GALT - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk. Profitability This table compares SQZ Biotechnologies and
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
Galectin Therapeutics Inc. (NASDAQ: GALT - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $3.04 and traded as high as $4.21. Galectin Therapeutics shares last traded at $4.15, with a volume of 291,096 shares. Wall Street Analysts Forecast Growth A number
NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.